VHL
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) (NCT03108066) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2017-04-24 |
Track VHL automatically
Every clearance here is in the API, with alerts when new ones post.